Please join Tectonic Therapeutic for a virtual key opinion leader (KOL) event featuring Hanny Al-Samkari, MD (Massachusetts General Hospital, Harvard Medical School), who will join company management to discuss the TX2100 program. The management team will review the target, mechanistic rationale and preclinical evidence supporting its GPCR antagonist strategy, and Dr. Al-Samkari will provide clinical context on Hereditary Hemorrhagic Telangiectasia (HHT), including disease burden, unmet medical need, and limitations of current treatment approaches.

The event will highlight Tectonic’s TX2100, a GPCR antagonist targeting a pathway that, together with its ligand, has been described to play a role in the formation of arteriovenous malformations (AVMs) and pathological angiogenesis. TX2100 is a potential first-in-class therapeutic candidate for the treatment of HHT, the second most common inherited bleeding disorder. Tectonic plans to initiate a Phase 1 clinical trial in 1Q 2026.

Formal presentations will be followed by a live question and answer session with Dr. Al-Samkari and company management.